Rubicon Research Ltd.

₹1,677.2

-40.1 (-2.3%)

RUBICON Share Price

Pharmaceuticals & Biotechnology

As on November 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 27,799 Cr

P/E Ratio112.22

Dividend Yield0.09 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,724.06	Bearish
10-DMA	1,712.24	Bearish
20-DMA	1,608.04	Bullish
50-DMA	1,650.07	Bullish
100-DMA	1,602.31	Bullish
200-DMA	1,254.03	Bullish

Historical Performance

1 Year

156.3%

3 Years

N/A

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	17,540	12,843	8,539	3,935	3,136
Total Expenditure	13,547	10,283	6,993	3,750	3,528
Other Income	87	119	185	255	168
Operating Profit	4,080	2,679	1,731	440	-224
Interest	422	368	313	190	97
Depreciation	453	366	390	361	340
Profit Before Tax	3,205	1,945	1,029	-110	-661
Consolidated Net Profit	2,467	1,344	910	-169	-671
Adjusted EPS	15	9	6	-1	-4

Compounded Sales Growth

10 Years:93.2

5 Years:41

3 Years:34.8

TTM:6.4

Compounded Profit Growth

10 Years:310.3

5 Years:51.7

3 Years:38.3

TTM:12.9

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:N/A

TTM:135.1

Return on Equity

10 Years:N/A

5 Years:-4.4

3 Years:6

last year:14.9

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	165	154	152	51	51
Total Reserves	12,410	4,993	3,460	2,667	2,881
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,890	1,226	1,511	1,020	706
Other Current Liabilities	1,537	930	751	458	328
Short Term Borrowings	677	2,901	2,642	1,958	914
Total Liabilities	23,137	14,497	11,086	7,497	5,595
Capital Work in Progress	405	67	96	245	26
Long Term Loans & Advances	252	409	157	131	282
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	465	381	536	315	177
Total Current Assets	16,818	10,634	7,632	5,016	3,284
Total Assets	23,137	14,497	11,086	7,497	5,595
Adjusted Book Value	76	33	24	18	19

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 112.22, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 167.0%, indicating sustained price appreciation.
The stock carries a low beta of 0.3, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹4080 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹17540 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 2349677.8

No. of Shares: 1401 (Approx)

Performance:135%

1349677.8

NIFTY Performance: -3%

1 day Top Gainers